Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to -$1.8 million.

  • Strata Critical Medical's Cash from Financing Activities fell 14445.96% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 million, marking a year-over-year decrease of 47882.6%. This contributed to the annual value of -$5.8 million for FY2024, which is 747763.16% down from last year.
  • Latest data reveals that Strata Critical Medical reported Cash from Financing Activities of -$1.8 million as of Q3 2025, which was down 14445.96% from -$1.1 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Cash from Financing Activities ranged from a high of $333.5 million in Q2 2021 and a low of -$4.2 million during Q1 2025
  • In the last 5 years, Strata Critical Medical's Cash from Financing Activities had a median value of -$731000.0 in 2024 and averaged $18.5 million.
  • As far as peak fluctuations go, Strata Critical Medical's Cash from Financing Activities skyrocketed by 171000.0% in 2021, and later plummeted by 1674347.83% in 2024.
  • Quarter analysis of 5 years shows Strata Critical Medical's Cash from Financing Activities stood at -$3.0 million in 2021, then skyrocketed by 68.51% to -$932000.0 in 2022, then surged by 97.53% to -$23000.0 in 2023, then crashed by 16743.48% to -$3.9 million in 2024, then skyrocketed by 53.87% to -$1.8 million in 2025.
  • Its Cash from Financing Activities stands at -$1.8 million for Q3 2025, versus -$1.1 million for Q2 2025 and -$4.2 million for Q1 2025.